about
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myelomaNovel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.Long-term complete remission in a multiple myeloma patient after Stevens-Johnson syndrome due to lenalidomide therapy.Human DKK1 and human HSP70 fusion DNA vaccine induces an effective anti-tumor efficacy in murine multiple myeloma.The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis.Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.
P2860
Q36778126-EF1EED73-7CCA-441C-89EE-73244C2325EDQ37260574-45264D9B-12FA-40A9-AA06-F1A9CCCD14B9Q38014834-8D18C304-15BE-4054-B185-E5D2B4821E98Q38090691-F4BD4A58-1B73-49D4-85FB-0DCD149291E7Q38526452-922C2824-E3EF-4042-91F8-0A88AC942305Q39265240-D3B4B0A3-9699-4564-AD93-C655B398195AQ45384970-576C3AD6-5B12-4775-AC74-91F21D909189Q48507398-F45C6512-07F2-449A-B4BB-94B85D728698Q54983490-C0E31B70-8006-4163-8140-1F17BDD09970Q55029794-22DE21A1-27E0-43BD-8677-5C76629FCDE0
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Novel immunotherapies
@ast
Novel immunotherapies
@en
type
label
Novel immunotherapies
@ast
Novel immunotherapies
@en
prefLabel
Novel immunotherapies
@ast
Novel immunotherapies
@en
P2860
P1433
P1476
Novel immunotherapies
@en
P2093
P2860
P304
P356
10.1097/PPO.0B013E3181C51F0D
P577
2009-11-01T00:00:00Z